The $945 Million Cash Transaction and Exclusive FAPI-74 Radiotracer Rights
GE HealthCare Technologies Inc. formally confirmed an agreement to acquire Sofie Biosciences from private equity firm Trilantic North America for $945 million in cash. Slated for formal closure in the first half of 2027 pending standard regulatory and antitrust clearances, the transaction will directly integrate Sofie into GE HealthCare’s high-performing Pharmaceutical Diagnostics (PDx) operating unit.
A principal catalyst of the transaction is securing exclusive United States territorial rights to FAPI-74, a high-affinity PET imaging agent currently advancing through Phase 3 clinical evaluation for broad-spectrum oncology diagnostics. Having already controlled licensing rights to the agent outside the United States, this transaction unifies global ownership under GE HealthCare, establishing a cohesive international commercialization roadmap.
The acquisition of Sofie Biosciences establishes a footprint for GE HealthCare in the time-critical 'final mile' of U.S. PET radiopharmaceutical supply.
Acquisition encompasses 15 specialized cGMP manufacturing sites and 21 cyclotron installations across the continental United States.

















